Skip to main content

Table 1 Summary of cases with ECMO of myocarditis from immune checkpoint inhibitors.

From: Fulminant myocarditis induced by immune checkpoint inhibitor nivolumab: a case report and review of the literature

Authors, year Age, sex Malignancy ICI Doses prior to myocarditis Treatments utilized Outcome
Arangalage et al. (2017) 35, F Melanoma Ipi 3 mg/kg,
Nivo 1 mg/kg
1 Intravenous solumedrol 1 g/day and IVIG followed by ECMO and plasma exchange followed by tacrolimus Survived
Frigeri et al. (2018) 76, F Metastatic
lung adenocarcinoma
(dose NA)
7 ECMO, IABP, intravenous methylprednisolone 5 mg/kg/day, plasmapheresis, infliximab
5 mg/kg, three doses
Yamaguchi et al. (2018) 60, M Melanoma Nivo
2 mg/kg
13 ECMO, IABP, intravenous prednisolone 1000 mg/day for 3 days + IVIG at 50 g/day for 2 days Survived
Imai et al. (2018) 70, M Squamous cell carcinoma of lung Pembro
(200 mg)
2 Intravenous methylprednisolone (1 g/day) for 3 days, IVIG 1 g/kg for 2 days, ECMO, IABP Died
  1. ECMO extracorporeal membrane oxygenation, ICI immune checkpoint inhibitors, IABP intraaortic balloon pump, IVIG intravenous immunoglobulin, ipi ipilimumab, nivo nivolumab, pembro pembrolizumab, mg/kg milligrams/kilogram body weight, NA not available